^(131)I联合碳酸锂治疗复杂Graves病探讨  

^(131)I Combined with Lithium Carbonate for the Treatment of Graves' Disease

作　　者：季小忠[1] 

机构地区：[1]南通大学附属海安医院,江苏海安226600

出　　处：《标记免疫分析与临床》2014年第4期409-410,共2页Labeled Immunoassays and Clinical Medicine

摘　　要：目的探讨131I联合碳酸锂治疗复杂Graves病的作用及安全性。方法回顾性分析131I联合碳酸锂治疗的70例Graves病合并肝功能损害、白细胞减少、房颤等患者的资料(联合组)。以同期的单用131I治疗的70例Graves病患者的资料为对照组,比较治疗后1个月、3个月、6个月时的效果。结果联合组取得很好疗效,而且比对照组更早改善症状。结论碳酸锂可以解决甲亢患者131I治疗时遇到的许多难题,因而131I联合碳酸锂治疗Graves病应该受到重视。Objective To explore the effect and safety of 131I combined Lithium carbonate for the treatment of complex Graves＇ diseases. Methods The clinical data of 70 patients with complex Graves＇ diseases combined treated with 131I combined Lithium carbonate such as liver dysfunction, leukopenia and arterial fibrillation were retrospective analyzed. The 70 patients with Graves＇diseases treated by 131I only at the same time were severed as controls for treatment effect comparison. Results The patents in combined treatment group got good effects and improved symptoms earlier than those in the control group. Conclusion The combined 131I and lithium carbonate for Graves＇ diseases treatment could solve many problems that patients meet during 131I therapy.

关 键 词：131I 碳酸锂 甲状腺功能亢进症 

分 类 号：R581.1[医药卫生—内分泌]